Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

21. Chronic kidney disease: Scenario: COVID-19

Chronic kidney disease: Scenario: COVID-19 Scenario: COVID-19 | Management | Chronic kidney disease | CKS | NICE Search CKS… Menu Scenario: COVID-19 Chronic kidney disease: Scenario: COVID-19 Last revised in May 2020 Scenario: COVID-19 From age 18 years onwards. How should my management vary when considering the possibility of COVID-19? In people with chronic kidney disease (CKD) and in the presence of the COVID-19 pandemic, National Institute of Health and Care Excellence (NICE) has made (...) when they should seek help and who to contact. Referrals to renal services To minimize risk from COVID‑19, NICE advises that clinicians should delay referral if the clinical need is not urgent, for example, if the person has mild-to-moderate proteinuria and a stable eGFR (including people with suspected inherited kidney disease). Continue to refer people for urgent outpatient appointments if there is a clinical need, for example, if the person has accelerated progression of CKD, which is defined

2020 NICE Clinical Knowledge Summaries

22. Chronic kidney disease: How should I assess suspected chronic kidney disease?

Chronic kidney disease: How should I assess suspected chronic kidney disease? Assessment | Diagnosis | Chronic kidney disease | CKS | NICE Search CKS… Menu Assessment Chronic kidney disease: How should I assess suspected chronic kidney disease? Last revised in May 2020 How should I assess suspected chronic kidney disease? If a diagnosis of chronic kidney disease (CKD) is , assess the person for possible associated clinical features. Ask about: General symptoms, such as lethargy, itch (...) , breathlessness, cramps (often worse at night), sleep disturbance, bone pain, or loss of appetite, vomiting, weight loss, and taste disturbance (often present with end-stage disease). Urine output, such as polyuria (tubular concentrating ability is impaired); oliguria; nocturia (due to impaired solute diuresis or oedema); or anuria (due to possible acute kidney injury [AKI], obstructive uropathy causing urinary retention; or end-stage renal disease). Any potentially , including over-the-counter or herbal

2020 NICE Clinical Knowledge Summaries

23. Chronic kidney disease: ACE-inhibitors and AIIRAs

Chronic kidney disease: ACE-inhibitors and AIIRAs ACE-inhibitors and AIIRAs | Prescribing information | Chronic kidney disease | CKS | NICE Search CKS… Menu ACE-inhibitors and AIIRAs Chronic kidney disease: ACE-inhibitors and AIIRAs Last revised in May 2020 ACE-inhibitors and AIIRAs Contraindications and cautions Use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated in people: With a history of angio-oedema associated with previous exposure to an ACE-inhibitor (...) -dose diuretics may result in volume depletion and a risk of hypotension. Lithium — reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration. Monitoring of serum lithium levels is recommended. NSAIDs — attenuation of antihypertensive effect may occur and there may be an increased risk of deteriorating renal function, including possible acute kidney injury and hyperkalaemia. Consider monitoring renal function after starting concomitant

2020 NICE Clinical Knowledge Summaries

24. Chronic kidney disease

anaemia, renal mineral and bone disorder, end-stage renal disease (ESRD), and increased all-cause mortality. CKD should be suspected in people with: Risk factors for CKD. An incidental finding of raised serum creatinine and/or eGFR of less than 60 mL/min/1.73 m 2 ; or markers of kidney damage. Possible clinical features of CKD (rare unless end-stage disease). If a diagnosis of CKD is suspected, initial investigations should be arranged and repeated as appropriate: Serum creatinine and eGFR. Early (...) Chronic kidney disease Chronic kidney disease | Topics A to Z | CKS | NICE Search CKS… Menu Chronic kidney disease Chronic kidney disease Last revised in May 2020 Chronic kidney disease (CKD) is an abnormality of kidney function or structure that is present for more than 3 months, with implications for health Diagnosis Management Prescribing information Background information Chronic kidney disease: Summary Chronic kidney disease (CKD) is a reduction in kidney function or structural damage

2020 NICE Clinical Knowledge Summaries

25. COVID-19 rapid guideline: chronic kidney disease

Patients known or suspected to have COVID-19 8 3 Managing chronic kidney disease (CKD) 9 Modifying usual care 9 Medicines 9 Monitoring CKD 10 4 Specialist services 11 Referrals to renal services 11 Renal ultrasound 11 Hospital admission 12 5 Advanced chronic kidney disease 13 6 Healthcare workers 14 COVID-19 rapid guideline: chronic kidney disease (NG176) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 14Overview (...) . Be aware that there is no evidence from clinical or epidemiological studies that ACE inhibitors or angiotensin receptor blockers might worsen COVID-19. See: • the Renal Association UK position statement on COVID-19 and ACE inhibitor/ angiotensin receptor blocker use COVID-19 rapid guideline: chronic kidney disease (NG176) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 14• the Renal Association guidance

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

26. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease

in HF patients and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . We conducted a systematic review evaluating the efficacy and safety of MRA in patients with HF and CKD. PubMed, Embase, and Cochrane Central databases were searched for relevant studies on patients with HF and reduced renal function (defined as eGFR <60 mL/min/1.73 m 2 ). Seven studies with 5,522 patients were included. We found 3 studies in patients with HFrEF, 1 study with HFpEF (...) Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily

2020 EvidenceUpdates

27. COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD)

, calcineurin inhibitors, and mTOR inhibitors for patients with COVID-19 who develop acute kidney injury requiring renal replacement therapy, see also see also for additional information Patients With Chronic Kidney Disease (CKD) General Consideration PubMed 32204907 Kidney international Kidney Int 20200307 patients with existing conditions can be more susceptible to COVID-19 and likely to experience more severe illness ( , , ) existing conditions include CKD, with any of the following decreased kidney (...) COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD) COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD) You need to enable JavaScript to run this app. Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow. Subscribe Already subscribed? Specialties 0 English COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD) Follow Share

2020 DynaMed Plus

28. Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. Full Text available with Trip Pro

Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. At least 30 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronic kidney disease (CKD).To compare the 30-day risk of encephalopathy in patients with CKD and newly prescribed baclofen at greater than or equal to 20 mg per day vs less than 20 mg per day. The secondary objective was to compare the risk of encephalopathy in baclofen users vs nonusers.Retrospective

2019 JAMA

29. Development of Risk Prediction Equations for Incident Chronic Kidney Disease. Full Text available with Trip Pro

Development of Risk Prediction Equations for Incident Chronic Kidney Disease. Early identification of individuals at elevated risk of developing chronic kidney disease (CKD) could improve clinical care through enhanced surveillance and better management of underlying health conditions.To develop assessment tools to identify individuals at increased risk of CKD, defined by reduced estimated glomerular filtration rate (eGFR).Individual-level data analysis of 34 multinational cohorts from the CKD (...) %) had a slope of observed to predicted risk between 0.80 and 1.25. Discrimination was similar in 18 study populations in 9 external validation cohorts; calibration showed that 16 of 18 (89%) had a slope of observed to predicted risk between 0.80 and 1.25.Equations for predicting risk of incident chronic kidney disease developed from more than 5 million individuals from 34 multinational cohorts demonstrated high discrimination and variable calibration in diverse populations. Further study is needed

2019 JAMA

30. Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant. (Abstract)

Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant. This article discusses potential indications for genetic testing in an African American patient with chronic kidney disease who is being evaluated for a kidney transplant. Two known risk variants in the APOL1 (apolipoprotein L1) gene predispose to kidney disease and are found almost exclusively in persons of African ancestry. APOL1 risk variants are considered, including (...) whether clinicians should incorporate genetic testing in the screening process for living kidney donors. In addition to APOL1 testing, the role of diagnostic exome sequencing in evaluating potential transplant recipients and donors with a positive family history of kidney disease is discussed.

2019 Annals of Internal Medicine

31. Chronic Kidney Disease Diagnosis and Management: A Review. (Abstract)

Chronic Kidney Disease Diagnosis and Management: A Review. Chronic kidney disease (CKD) is the 16th leading cause of years of life lost worldwide. Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death.Defined as a persistent abnormality in kidney structure or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg (...) per 24 hours) for more than 3 months, CKD affects 8% to 16% of the population worldwide. In developed countries, CKD is most commonly attributed to diabetes and hypertension. However, less than 5% of patients with early CKD report awareness of their disease. Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies. Optimal management of CKD includes cardiovascular risk

2019 JAMA

32. Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines

Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Last updated: January 14, 2019 Project Number: RB1297-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of dietary/nutrition priority screening tools for in-patients and outpatients with chronic kidney disease? What are the evidence-based guidelines for the use of dietary/nutrition prioritization tools for the delivery of nutritional therapy in the chronic kidney disease setting? Key Message One non-randomized study and three evidence based guidelines were identified regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

33. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. Full Text available with Trip Pro

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update

2019 Annals of Internal Medicine

34. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. (Abstract)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluated use of the potassium binder patiromer to allow more persistent use (...) of spironolactone in patients with chronic kidney disease and resistant hypertension.In this phase 2 multicentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged 18 years and older with chronic kidney disease (estimated glomerular filtration rate 25 to ≤45 mL/min per 1·73 m2) and uncontrolled resistant hypertension from 62 outpatient centres in ten countries (Bulgaria, Croatia, Georgia, Hungary, Ukraine, France, Germany, South Africa, the UK, and the USA). Patients meeting all

2019 Lancet

35. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Full Text available with Trip Pro

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention).In CREDENCE (Canagliflozin and Renal Events in Diabetes (...) ]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome).Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease.URL: https

2019 EvidenceUpdates

36. eHealth interventions for people with chronic kidney disease. Full Text available with Trip Pro

eHealth interventions for people with chronic kidney disease. Chronic kidney disease (CKD) is associated with high morbidity and death, which increases as CKD progresses to end-stage kidney disease (ESKD). There has been increasing interest in developing innovative, effective and cost-efficient methods to engage with patient populations and improve health behaviours and outcomes. Worldwide there has been a tremendous increase in the use of technologies, with increasing interest in using eHealth (...) interventions to improve patient access to relevant health information, enhance the quality of healthcare and encourage the adoption of healthy behaviours.This review aims to evaluate the benefits and harms of using eHealth interventions to change health behaviours in people with CKD.We searched the Cochrane Kidney and Transplant Register of Studies up to 14 January 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through

2019 Cochrane

37. Chronic renal diseases and pregnancy

.” International Journal of Women’s Health 8 (July): 273–85. Gonzalez Suarez, Maria L., Andrea Kattah, Joseph P. Grande, and Vesna Garovic. 2018. “Renal Disorders in Pregnancy: Core Curriculum 2019.” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, August. https://doi.org/10.1053/j.ajkd.2018.06.006. Hladunewich, Michelle A. 2017. “Chronic Kidney Disease and Pregnancy.” Seminars in Nephrology 37 (4): 337–46. Imbasciati, Enrico, Gina Gregorini, Gianfranca Cabiddu (...) in English (4 pages) 2. Entire guideline in Danish (35 pages) Summary of clinical recommendations: Chronic Kidney Disease and pregnancy: CKD Recommendations Level of evidence Recommendation Preconception Counselling in cooperation with a nephrologist and an obstetrician with special interest in nephrology A Level of renal impairment, presence of hypertension and proteinuria are the strongest prognostics for the outcome of the pregnancy as well as the risk of progression of renal disease /progression

2019 Nordic Federation of Societies of Obstetrics and Gynecology

38. Tolvaptan (Jinarc ) for the treatment of chronic kidney disease - alteration of the specific conditions

Tolvaptan (Jinarc ) for the treatment of chronic kidney disease - alteration of the specific conditions Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions | Report | National Health Care Institute You are here: Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions Search within English part of National Health Care Institute Search Tolvaptan (Jinarc ®) for the treatment of chronic kidney (...) supportive care for ADPKD patients with chronic kidney disease (CKD) stages 1 to 3. For the effectiveness of tolvaptan in patients with CKD stage 3b, the evidence was scant. As a result, reimbursement is currently possible based on the following condition: Only for an insured person aged 18 years and older with autosomal dominant polycystic kidney disease (ADPKD) with chronic kidney disease (CKD) in stages 1 to 3a at the start of the treatment, with evidence of rapidly progressing disease, and in line

2019 National Health Care Institute (Zorginstituut Nederland)

39. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Full Text available with Trip Pro

Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Intradialytic hypotension (IDH) is a common complication of haemodialysis (HD), and a risk factor of cardiovascular morbidity and death. Several clinical studies suggested that reduction of dialysate temperature, such as fixed reduction of dialysate temperature or isothermal dialysate using a biofeedback system, might improve the IDH rate.This review aimed to evaluate (...) the benefits and harms of dialysate temperature reduction for IDH among patients with chronic kidney disease requiring HD, compared with standard dialysate temperature.We searched Cochrane Kidney and Transplant's Specialised Register up to 14 May 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search

2019 Cochrane

40. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. (Abstract)

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bone demineralisation and is associated with adverse kidney outcomes and mortality. Veverimer, a non-absorbed, counterion-free, polymeric drug candidate selectively binds and removes hydrochloric acid from the gastrointestinal (...) lumen.We did a multicentre, randomised, blinded, placebo-controlled, 40-week extension of a 12-week parent study at 29 sites (hospitals and specialty clinics) in seven countries (Bulgaria, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA). Eligible patients were those with chronic kidney disease (estimated glomerular filtration rate 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate 12-20 mmol/L), who had completed the 12-week parent study, for which they were randomly assigned

2019 Lancet Controlled trial quality: predicted high